Trial Profile
A Phase 1 Study of MORAb-202 in Subjects With Solid Tumors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 08 Jan 2024
Price :
$35
*
At a glance
- Drugs Farletuzumab ecteribulin (Primary)
- Indications Adenocarcinoma; Advanced breast cancer; Carcinoma; Endometrial cancer; Fallopian tube cancer; Non-small cell lung cancer; Ovarian cancer; Peritoneal cancer; Solid tumours; Triple negative breast cancer
- Focus Adverse reactions; First in man; Pharmacodynamics
- Sponsors Eisai Co Ltd
- 09 Nov 2022 Status changed from active, no longer recruiting to completed.
- 28 Oct 2022 Results of exploratory biomarker analysis (n=58) assessing MORAb-202 induced pharmacological effects in patients with ovarian cancer to examine its clinical mechanism of action(MoA), presented at the 34th EORTC-NCI-AACR Symposium on molecular targets and cancer therapeutics.
- 18 Oct 2022 Planned End Date changed from 1 Oct 2022 to 31 Oct 2022.